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Development of nanoscale carrier systems for targeted drug delivery is crucial for cancer treatment. The
current methods of drug delivery exhibit some problems such as lack of therapy eﬃciency at the desired
parts of the body, degradation of the drug before reaching the desired tissue and limitations in cellular
penetration. In this work, a novel drug delivery platform was developed to overcome these problems and
to enable speciﬁc and eﬃcient uptake into the cells. The surface of the synthesized polyethylene
glycolated niosomes (PEGNIO) was modiﬁed with cell penetrating peptide (CPP) and cell speciﬁc MUC1
(S2.2) aptamer, and doxorubicin (DOX) as a cancer model drug was encapsulated in this platform.
Fluorescence microscopy and ﬂow cytometry analysis were used to investigate the cellular uptake and
intracellular distribution of the DOX loaded niosomal formulation. In vitro cytotoxicity studies were
carried out using MUC1 positive HeLa and negative U87 cells. Moreover, dynamic light scattering (DLS),
zeta potential measurements and ﬂuorescence absorption spectroscopy were performed to determine
the vesicle size, as well as charge and spectroscopic properties of the conjugates. From these results,
this novel aptamer mediated niosomal drug delivery platform may have application potential in targeted
drug delivery towards MUC1-overexpressing tumors.Introduction
A drug delivery system (DDS) is described as a formulation that
enables the introduction of drug molecules into the body with
improved eﬃcacy and safety. Due to the rapid progress of
nanotechnology, numerous nanocarriers have been developed
to securely deliver drugs into target sites. New targeting agents,
including aptamers, short peptides, and small molecules have
recently become promising targeting ligands to design novel
drug delivery systems.
The current treatment options for cancer are surgical oper-
ation, radiation and chemotherapy or a combination. The
therapeutic eﬃcacy of many anticancer drugs is limited by their
poor penetration into tumor tissue and by their side eﬀects on
healthy cells.1 To overcome these limitations, development of
a novel carrier platform for specic drug uptake into the cell
with an optimal dose at high eﬃciency is important. Therefore,
anticancer drugs can be conjugated with biomolecules exhib-
iting potential for cellular targeting and penetration and can be
delivered to the desired site of action by multi-functional carrier
platforms. Vesicular nanocarriers have received great attention
as potential drug carrier systems. Nonionic surfactant based
vesicles “niosomes” are one class of vesicular nanocarriers
which can accommodate a large number of drugs with a wideiversity Hannover, Callinstreet 5, 30167
-hannover.de
tion (ESI) available. See DOI:
8range of solubility.2–4 Due to their low cost, long term storage
stabilities and lower toxicity of niosomes have been used for
drug delivery.5–7 The addition of polyethylene glycol (PEG) to the
nanocarrier surface increases the steric stabilization of the
nanoparticle and allows for further surface modications to
design specic drug delivery systems. It is generally thought
that PEGylation protects the delivery systems against the
immune system and thereby prolong circulation life times.8
In solid tumors, the penetration of the tissue by the anti-
cancer drug is limited which causes reduced eﬃcacy and the
development of drug resistance.9 A promising approach to
overcome the cellular barrier is based on the use of certain
peptides namely cell penetrating peptides (CPPs), able to
translocate across the cell membrane and deliver their payload
intracellularly within minutes.10 CPPs consist of small cationic
or amphipathic peptides that aid the uptake of attached cargos
into living cells. A wide variety of small molecules and
biomolecules including plasmid DNA, siRNA, oligonucleotides
and peptide nucleic acid molecules have been attached to these
peptides and were subsequently internalized.11–13 The ability of
CPPs to translocate biologically active molecules into cells
makes these peptides promising candidates for theranostic
applications.14 TAT is one of the smallest polycationic CPPs
composed of arginine and lysine residues. Studies on the
binding aﬃnities of cationic TAT peptides indicate that these
peptides strongly bind electrostatically to the various anionic
species (e.g. heparan sulphate proteoglycans) present at the
extracellular surface of cell membranes.15,16 The exact molecular
mechanism of cellular entry of CPPs is currently not fullyThis journal is © The Royal Society of Chemistry 2016
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View Article Onlineunderstood. Former studies indicated that in general uptake
occurs by endocytosis (or more specically macropinocytosis)
and direct membrane translocation.17 The lack of cell specicity
remains the major drawback for the clinical application of
CPPs.18
Receptors that are over-expressed in many cancer cells are
suitable targets to achieve a more specic delivery. MUC1 is
a large transmembrane glycoprotein overexpressed in most
malignant adenocarcinoma, including ovarian, lung, pancreatic,
prostate, and breast cancers, making it an ideal target molecule
for chemotherapeutics.19 Aptamers are short oligonucleotides
that are capable to selectively bind their corresponding
target.20–22 These reagents are selected by an in vitro process
called SELEX, (systematic evolution of ligands by exponential
enrichment).23 Several MUC1 aptamers were developed by Fer-
reira et al. and S2.2 is a 25-nucleotide truncated version of the
original MUC1 aptamer. It binds MUC1 protein with high
specicity and aﬃnity with a KD of 0.135 nM.24,25 S2.2 has been
used in a few targeted delivery systems. Yu et al. used MUC1
aptamer to target paclitaxel (PTX) loaded poly(lactic-co-glycolic-
acid) (PLGA) nanoparticles.26 Furthermore PEG-modied
MUC1 targeting doxorubicin (DOX) was designed and the
aptamer–doxorubicin complex was prepared by intercalation of
the aptamer with DOX by Tan et al.27 Recently, Liu et al.
synthesized vinorelbine (VRL) loaded and MUC1 aptamer
modied lipid–polymer hybrid nanoparticles.22
In this study, polyethylene glycolated niosomes (PEGNIO)
were prepared from span60, cholesterol and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[maleimide (polyethylene
glycol)-2000] (DSPE-PEG(2000) Maleimide). DOX was encapsu-
lated into the PEGNIO. The niosomes were characterized with
respect to size, morphology and drug encapsulation eﬃciency.
Cysteine-modied cell penetrating peptide (CysTAT) was
conjugated to the amine group of MUC1 aptamer in the pres-
ence of a crosslinking agent bis(sulfosuccinimidyl)suberate
(BS3). Subsequently CysTAT–MUC1 conjugate was attached to
DOX encapsulated PEGNIO (PEGNIO/DOX) via the formation of
a thioether linkage. The anticancer activity of DOX-loaded tar-
geted vesicles was studied in HeLa (cervical cancer cells) and
U87 (human glioblastoma cells) cell lines by evaluating the
cellular uptake and cytotoxicity. The designed nanoparticular
drug delivery system composed of aptamer–CPP–PEGNIO was
rst fabricated in this study. Our ndings suggest that this
platform can serve as a delivery vehicle for cancer cells over-
expressing MUC1.
Materials and methods
Materials
Amine and Cy5 modied MUC1 aptamer S2.2 (50-NH2-GCA GTT
GAT CCT TTG GAT ACC CTG G-30), (50-Cy5-GCA GTT GAT CCT
TTG GAT ACC CTG G-30) were purchased from Integrated DNA
Technologies. CysTAT with CYGRKKRRQRRR–NH2 sequence
was obtained from GenScript. DSPE-PEG(2000) Maleimide was
provided by Avanti. Span60, cholesterol, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazoliumbromide (MTT), 4,6-diamino-2-
phenylindol (DAPI) and Dulbecco's Modied Eagle MediumThis journal is © The Royal Society of Chemistry 2016(DMEM) were ordered from Sigma Aldrich. RNAtidy G and
sodium dodecyl sulfate (SDS) were purchased from Applichem.
BS3 was ordered from Covachem. Doxorobucin (hydrochloride)
was purchased from Cayman Chemical. GeneRuler 100 bp DNA
ladder and dNTP Set (100 mM solutions) were obtained from
Fermentas. M-MLV reverse transcriptase and its M-MLV RT 5
buﬀer as well as GoTaq polymerase and its 5 Green GoTaq
reaction buﬀer were provided from Promega. PCR primers were
synthesized by Life Technologies.
Preparation of PEGylated niosomes
Multi lamellar vesicles (MLVs) of PEGNIO were prepared by the
thin lm hydration method.28 Span 60, cholesterol, and DSPE-
PEG(2000) Maleimide were dissolved in 1.0 mL chloroform in
a round-bottom ask with the molar ratio of 4.95 mM : 4.95
mM : 0.1 mM. The solvent was evaporated with constant rota-
tion at 38 C under reduced pressure to form a thin lipid lm.
Then the thin lm was hydrated with 1.0 mL of distilled water
for preparing empty niosomes, or a doxorubicin solution (0.22
 103 M in water) to obtain PEGNIO/DOX conjugate at 60 C
for 60min. Aerward the niosomal suspension was equilibrated
at room temperature overnight, to complete annealing and
partitioning of the drug between the lipid bilayer and the
aqueous phase.5 Small unilamellar vesicles (SUVs) were prepared
starting from MLVs by extruding the niosomes 11 times through
0.4 mm and 0.1 mm pore size polycarbonate lters using mini-
extruder set (Avanti polar lipids). Niosomes were puried by
dialysis against water for 3 h using 6–8 kDa dialysis bag.
Synthesis and characterization of CysTAT–MUC1 conjugate
The conjugation between CysTAT and amine modied MUC1
aptamer was performed using an amine to amine crosslinker
BS3. 35 mL containing 5 nmol amine modied MUC1 aptamer,
30 mL containing 20 nmol CysTAT peptide and 150 mL con-
taining 1.75 mmol BS3 were mixed in 85 mL 0.1 M sodium
phosphate including 0.15 M sodium chloride at pH 7.4 and
incubated at room temperature for 1 h. Once the reaction was
completed, 300 mL 1.0 M Tris buﬀer was added to quench the
reaction for 20 minutes at room temperature. Unreacted
peptides and quenched crosslinkers were removed through
dialysis against PBS (pH 7.2) using 3.5 kDa dialysis bag. During
this reaction aptamer–aptamer and peptide–peptide conjuga-
tion can occur. Denaturing urea polyacrylamide gel electro-
phoresis (Urea PAGE) and HPLC were used for the
characterization of CysTAT–MUC1. Urea PAGE was performed
according to manufacturer's instructions (QIAGEN). Briey 15%
acrylamide/urea gel was prepared and run for 30 min at 200 V.
The samples were heated at 95 C for 2 min and then they were
immediately transferred onto ice. The samples were loaded
onto the gel and the gel was run for 1.5 h at 200 V. Aerward the
gel was stained with methylene blue solution and documented
using an INTAS UV documentation system. HPLC measure-
ments and carried out using VWR Hitachi Chromaster. For the
analysis, a DAD detector and Kinetix 2.6 mm C8 100 A˚, 150 
4.6 mm (Phenomenex) column were used. Detection was per-
formed at 214 nm at room temperature. The mobile phaseRSC Adv., 2016, 6, 87910–87918 | 87911
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View Article Onlineconsisted of 0.065% triuoroacetic acid (TFA) in water and
0.05% TFA in acetonitrile with a ow rate of 1.0 mL min1.Conjugation CysTAT–MUC1 to PEGNIO/DOX
CysTAT–MUC1 was conjugated to PEGNIO/DOX via thiol group
of cysteine to maleimide group on PEGNIO resulting in the
formation of a thioether linkage.29,30 Maleimide group reacts
specically with thiol-groups in the pH range 6.5–7.5. 100% of
the prepared CysTAT–MUC1 conjugate in PBS (pH 7.2) and 50%
of the prepared PEGNIO/DOX were mixed and incubated over-
night at room temperature. Aer completing the reaction
between sulydryl group of CysTAT and maleimide group of
DSPE-PEG(2000) Maleimide, the nal PEGNIO/DOX/CysTAT–
MUC1 conjugate was puried using 14 kDa dialysis bag to
remove unbound CysTAT–MUC1. Schematic representation of
niosome synthesis, drug encapsulation and the bioconjugation
processes are shown in Scheme 1.Measurement of particle size, distribution and zeta potential
Size, size distribution and zeta potential of niosomes were
determined by dynamic light scattering (DLS) analysis using
Malvern Zetasizer Nanoseries-Nano-ZS. The polydispersity index
(PDI) was used as ameasure of the width of size distribution. PDI
less than 0.3 corresponds to a homogenous population for
colloidal systems.31 Each sample was measured three times.Stability
The stability of DOX loaded niosomal formulations was tested
via DLS analysis. Aer the synthesis of PEGNIO/DOX andScheme 1 Schematic representation of drug the encapsulation and
the bioconjugation process.
87912 | RSC Adv., 2016, 6, 87910–87918PEGNIO/DOX/CysTAT–MUC1, these conjugates were stored at
4 C in the dark. The particle size and PDI values were measured
for 2 months. Additionally the particle size of PEGNIO/DOX/
CysTAT–MUC1 was measured in cell culture media before and
aer the incubation at 37 C for 24 h.
Entrapment eﬃciency
The drug encapsulation eﬃciency was determined using the
dialysis technique.32 According to this method, directly aer the
preparation 1.0 mL of PEGNIO/DOX and 1.0 mL of PEGNIO/
DOX/CysTAT–MUC1 dispersions were dropped into two dialysis
bags (12–14 kDa) and immersed in 100 mL of distilled water
with magnetic stirring at 100 rpm. Samples were dialyzed for 3
h. The percent of encapsulation eﬃciency (E%) was expressed
as the percentage of the drug entrapped in niosomes (and thus
not removed via dialysis) referred to the initial amount of drug
that is present in the nondialyzed sample. It was determined by
diluting 50 mL of dialyzed and 50 mL of nondialyzed niosomes in
1.0 mL of methanol. This step is essential for breaking the
niosomal membrane, thereby releasing the entrapped DOX.
Subsequently, the amount of DOX was determined by HPLC
using a C18 column (Phenomenex Kinetix, 4.6  100 mm,
2.6 mm) at 35 C and a UV detector was conducted at 254 nm.
The mobile phase consisted of methanol and water (60/40, v/v)
containing 0.1% formic acid and 0.1% ammonia solution (25%)
with a ow rate of 1.0 mL min1.33 The stock solutions of DOX
were prepared at 1.0 mg mL1 in methanol and further diluted
with methanol in the concentration range 1.0–200 mg mL1. The
amount of encapsulated DOX was calculated according to the
calibration curve (y¼ 120 777x 67 040, R2¼ 0.9984). The limit
of detection (LOD) and limit of quantication (LOQ) for DOX
were found to be 6.12 mg mL1, 18.55 mg mL1 respectively
based on 3.3s/slope and 10s/slope formulations.34
Drug release
Drug release experiments were performed using the dialysis
method. The DOX-loaded niosome solutions were prepared and
transferred into a dialysis membrane tubing (Thermo, Slide-
ALyzer MINI Dialysis Devices, 10k MWCO). The tubing was
immersed in 10 mL of the PBS buﬀer (pH 5.6 and 7.4), placed in
an incubator at 37 C and stirred at 100 rpm. At specic time
intervals, 0.5 mL samples were removed from the release
medium and replaced with the same volume of fresh buﬀer. A
calibration curve was established with a known concentration
of free DOX by uorescence emission measurements at 595 nm
using NanoDrop 3300. The amount of released DOX was
calculated according to the calibration curve (y ¼ 254.93x 
30.74, R2 ¼ 0.9960, LOD ¼ 0.61 mg mL1, LOQ ¼ 1.84 mg mL1).
Cell culture
HeLa and U87 cell lines were provided from German Collection
of Microorganisms and Cell Cultures (DSMZ). Both cell lines
were grown in DMEM containing 10% fetal calf serum (FCS)
and 1.0% penicillin/streptomycin (P/S). All cells were cultivated
inmedium and incubated with samples and reagents at 37 C in
a humidied environment with 5.0% CO2.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineMUC1 expression on cell surfaces
PCR and ow cytometry analysis were used to conrm expression
of the MUC1 receptor in HeLa and lack of expression in U87 cells.
Total cellular RNA of the cells was isolated using Trizol reagent
(Invitrogen) and transcribed into cDNA. The primers were
designed with Lasergene Primer Select Soware using the NCBI
reference mRNA sequence for Homosapiens mucin 1, cell surface
associated (MUC1), transcript variant 1 (NM_002456.5). The
primer sequences are as follows: MUC1 forward 50-TAC CGA TCG
TAG CCC CTA TG-30 and reverse 50-CCA CAT GAG CTT CCA CAC
AC-30. The human housekeeping gene hypoxanthine phosphor-
ibosyltransferase (HPRT) was additionally used to prove the
successful synthesis of cDNA. The primer sequences are: HPRT
forward 50-AAG CTT GCT GGT GAA AAG GA-30 and reverse 50-AAG
CAG ATG GCC ACA GAA CT-30. The protocol described in our
previous publication was used in the polymerase chain reac-
tions.35 The annealing temperature of 60 C was used for MUC1
and HPRT during PCR experiments. PCR products were separated
in 1.5% agarose gel in TAE buﬀer and stained with 5.0 mL/100 mL
buﬀer Roti-Safe Gel Stain ready to use by Thermo. The gel was run
using the Thermo EC electrophoresis unit at 100 V for 60min and
documented using an INTAS UV documentation system.
For ow cytometry studies, 5  105 cells were collected. 100
mL of 5.0 mM Cy5 labelled MUC1 aptamer in PBS were added to
the cells and the cell suspension was shaken at room temper-
ature for 1 h with 500 rpm in the dark. The cells were washed
once in 300 mL of PBS to remove unbound aptamer. Before ow
cytometric analysis, cells were resuspended in 500 mL of PBS
and the stained cells were analyzed in a BD Accuri C6 ow
cytometer. At least 20 000 gated events were observed in total
and living cells were gated in a dot plot of forward versus side
scatter signals. For drawing dot plots and histograms the BD
Accuri C6 soware was used.Cytotoxicity
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assays were used to determine cytotoxicity of the nioso-
mal formulations. Cells (8  103) were seeded out in 96-well
tissue plates (Sarstedt, USA) in a volume of 200 mL and cultivated
for three days. Aer this cultivation time cells were washed once
in PBS and treated with SUVs (PEGNIO, PEGNIO/DOX, PEGNIO/
DOX/CysTAT–MUC1) and free DOX for 24 h and 48 h. The
equivalent concentration of free DOX was used in niosomal
formulations. Then the samples were removed and cells were
incubated in 110 mL per well 10%MTT solution (5.0 mg mL1 in
PBS) in medium for 4 h. During this incubation time, formazan
complex was produced by the cells. 100 mL SDS solution (1.0 g
SDS in 10 mL 0.01 M HCl) was added to each well to release the
purple colored salt from the cells. Aer 24 h of incubation, UV-
vis absorption was measured at 570 nm to 630 nm as the refer-
ence wavelength using a microplate reader Epoch Biotek.Cellular uptake and internalization
The DOX uptake by HeLa and U87 cells for diﬀerent DOX
formulations was analyzed by ow cytometry. HeLa and U87This journal is © The Royal Society of Chemistry 2016cells were treated with PEGNIO/DOX, PEGNIO/DOX/CysTAT–
MUC1 and free DOX for 2 h and treated cells were washed two
times with PBS, and then analyzed in a BD Accuri C6 ow
cytometer.
Cellular internalization of PEGNIO/DOX/CysTAT–MUC1 was
determined via uorescence microscopy studies. HeLa and U87
cells were cultivated for 2 days on the chamber slides (m slides 8
well purchased at ibidi GmbH) in a volume of 200 mL of the
medium. PEGNIO/DOX/CysTAT–MUC1 was diluted with
medium and then added to the cells. The cells were incubated
for 4 h at 37 C and washed once in PBS. Aerward 100 mL DAPI
solution (1.0 mg mL1) was added to the cells and incubated for
15 min. Aer DAPI staining, the cells were washed with PBS
once. Images were taken using an OLYMPUS BX41 uorescence
microscope equipped with an OLYMPUS SC30 camera.
Statistical analysis
Statistical analysis was performed using the GraphPad InStat
statistical soware. All experiments were repeated three times.
The paired t-test was performed. The diﬀerence between two
groups was considered to be signicant when the p value was
less than 0.05.
Results
Doxorubicin is one of the most extensively used broad-spectrum
anticancer drugs. It accumulates inside the cell nucleus where it
intercalates into DNA and inhibits the progression of topo-
isomerase II to cause DNA damage and cleavage.36,37 Long
treatment durations and toxic side eﬀects are inconvenient in
the use of conventional chemotherapeutics.38 Recent studies
show that, biocompatible nanoparticles, with an increased
surface area to volume ratio can overcome non-cellular and
cellular-based mechanisms of resistance and increase the
selectivity of drugs towards cancer cells, while reducing their
toxicity towards normal tissues.39 The addition of PEG to the
nanoparticle surface prolongs vesicles residence time in blood
and accumulation at the pathological sites.5 Taking this into
consideration, we decided to use PEGylated niosomes for
obtaining aptamer targeted-cell penetrating vesicular systems.
Conjugation and characterization of CysTAT–MUC1
BS3 is an amine reactive, homobifunctional, sulfo-NHS ester,
crosslinking reagent.40 The reactivity of the sulfo-NHS esters is
highly reactive toward amines in the pH range of 7–9. The
amine modied MUC1 aptamer was reacted with the –NH2
group in the CysTAT peptide in the presence of BS3 to produce
the CysTAT–MUC1 conjugates. Besides the desired conjugate
CysTAT–MUC1, the reaction can also result in dimers of MUC1
aptamer and peptide. In order to investigate the product spec-
trum of the crosslinking reaction, gel electrophoresis was per-
formed. Free MUC1 aptamer and CysTAT–MUC1 were applied
to Urea PAGE. A single band was observed for free aptamer. In
the case of CysTAT–MUC1 conjugate double bands were
observed (Fig. S1†). In the double bands, rst band indicates
CysTAT–MUC1 conjugate and the second one exhibits unboundRSC Adv., 2016, 6, 87910–87918 | 87913
Table 1 Characterization of PEGNIO formulations incorporating DOX
Samples
Size (nm) intensity
(%) (mean  SD)
Polydispersity
index (PDI) Zeta potential (mV) Entrapment eﬃciency (E%)
PEGNIO 151.0  36 0.244 4.96  0.43 —
PEGNIO/DOX 152.7  34 0.214 3.56  0.27 39.52  1.8
PEGNIO/DOX/CysTAT–MUC1 164.5  40 0.275 8.62  0.50 37.48  2.1
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View Article Onlineaptamers in the conjugate. Additionally, the conjugation of
aptamer and peptide was proven by HPLC analysis. For this aim,
chromatograms of MUC1 aptamer, BS3 crosslinker, Cys-TAT
peptide were compared with chromatogram of CysTAT–MUC1
conjugate (Fig. S2†). No peaks were observed for MUC1 aptamer
in this HPLC method. CysTAT peptide and BS3 crosslinker have
diﬀerent retention times 7.75 and 8.67 respectively, showed that
there is no interference during the analysis of the CysTAT–MUC1
conjugates. The conjugation eﬃciency was about 82% in
accordance with the integrated areas of CysTAT peptide before
and aer conjugation. Besides CysTAT–MUC1, the conjugation
can also result in aptamer and peptide dimers. Nonetheless,
since these side products are not able to bind to maleimide
group of PEGNIO (due to the lack of –SH group), we used to the
as prepared conjugate with no additional purication.Fig. 1 In vitro cumulative release of DOX from PEGNIO/DOX/Cys-
TAT–MUC1 at pH 7.4 and 5.6.Synthesis and characterizations of DOX loaded niosomal
formulations
PEGylated niosomes were prepared by the thin lm layer
hydration technique, using span60:cholesterol:DSPE-PEG(2000)
Maleimide. 0.22 mM doxorubicin solutions were used in the
preparation of loaded vesicles. CysTAT–MUC1 was conjugated
to PEGNIO/DOX to obtain targeted drug delivery system. The
size of nanocarriers is very important for eﬀective accumulation
in tumor by enhanced permeability and retention eﬀect (EPR)
and cellular internalization. The mean diameters of empty and
doxorubicin-loaded niosomal formulations, along with the
corresponding polydispersity index (PDI), doxorubicin entrap-
ment eﬃciency (E%) values, and zeta potential values are listed
in Table 1. The empty vesicle size was analyzed to be 151.0  36
nm. The hydrodynamic diameter did not change aer DOX
loading (152.7  34 nm) but aer conjugation with CysTAT–
MUC1 it increased to 164.5  40 nm. The stealth niosomes
showed zeta potential values close to 0 mV but the surfaces of
nanoparticles was graed with PEG to improve water solubility
and avoid aggregation.5,41,42 Due to the presence of PEG in the
niosome structure, no aggregation was observed. DOX loading
inuenced the zeta potential of the vesicles. The change in the
zeta potential may be a result of DOX intercalation in the vesicle
membrane.5,43,44 Conjugation of CysTAT–MUC1 increased nio-
some size, corresponding with the presence of the aptamer on
the niosomal surface increasing the hydrodynamic diameter.
Moreover, the negatively charged DNA aptamer reduced the
surface potential of the niosome.29 PDI ranged from 0.275 to
0.214, demonstrating that the vesicle population is relatively
homogeneous in size. The DOX entrapment eﬃcacy (E%) was
calculated to be around 39% and 37% for PEGNIO/DOX and87914 | RSC Adv., 2016, 6, 87910–87918PEGNIO/DOX/CysTAT–MUC1 respectively. The stability of nio-
somal DOX formulations was tested via DLS analysis and no
changes were observed in the size and PDI values aer two
months storage at 4 C in the dark (data not shown). Addi-
tionally, PEGNIO/DOX/CysTAT–MUC1 sample was diluted in
cell culture media and was incubated at 37 C for 24 hours. The
size of the sample was measured before and aer incubation
and no changes were observed.Drug release
Sustained drug release is one of the important properties of
nanoscale drug delivery systems that will minimize side eﬀects
of the drug. In vesicular drug carrier systems, the drug release
occurs by passive transport of the drug through the membrane
bilayer.45 The release of DOX from PEGNIO/DOX/CysTAT–MUC1
was investigated using dialysis methods at pH 7.4, which was
chosen in accordance with physiological conditions and in an
acidic environment (pH 5.6). The solutions were taken out at
specic intervals and measured by uorescence emission
measurements at 595 nm to determine the amount of DOX that
has been released. The in vitro DOX release proles from
PEGNIO/DOX/CysTAT–MUC1 showed the faster release of DOX
under acidic environments than that at neutral pH (Fig. 1).
Within 48 h, the release of DOX was 30% and 52% at pH 7.4 and
pH 5.6 respectively. This can be explained by the higher solu-
bility of DOX at the lower pH.46 Especially, the pH change from
7.4 to 5.6 corresponds to the pH change from the normalThis journal is © The Royal Society of Chemistry 2016
Fig. 2 Image of 1.5% agarose gel with results of PCR for HPRT gene
and MUC1 expression in HeLa and U87 cells (a and b). Flow cytometry
analysis of MUC1 expression on HeLa and U87 cells using Cy5-labelled
aptamer S2.2 (c).
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View Article Onlinephysiological environment in body circulation to the intracel-
lular tumor tissue. According to results this conjugate is ex-
pected to be a promising drug delivery system for the tumor-
targeted delivery of DOX.Fig. 3 Flow cytometric measurement of DOX uptake by HeLa (a) and
U87 cells (b) after incubating with PEGNIO/DOX, PEGNIO/DOX/Cys-
TAT–MUC1 and free DOX. Histogram of binding of PEGNIO/DOX/
CysTAT–MUC1 to MUC1 positive HeLa cells and MUC1 negative U87
cells (c).Conrmation of MUC1 receptor expression on the cell surface
To test PEGNIO/DOX/CysTAT–MUC1 as a targeted drug delivery
system in vitro, rst the expression of MUC1 was evaluated in
HeLa and U87 cells. Gene expression of MUC1 was investigated
at the mRNA level using polymerase chain reaction (PCR) and at
the cell surface protein level using ow cytometry. Agarose gel
analysis with the results of PCR experiments is shown in Fig. 2.
The housekeeping gen (HPRT) was measured as a control for
both HeLa and U87 cells (Fig. 2a and b). Bands corresponding to
housekeeping genes were observed for both cell types (263 bp)
conrming the success of RNA extraction and PCR. Fig. 2a
demonstrates that HeLa cells show a high level of transcription
of the MUC1 gene, which results in a strong band at the expected
base pair length of 283 bp. No corresponding band was observed
in U87 cells, thereby indicating the lack of expression of MUC1.
The PCR results were also conrmed by using Cy5 labeled MUC1
aptamer in ow cytometry. Cells were treated with a Cy5 labeled
MUC1 aptamer. Aer the treatment, the mean uorescence
intensity wasmeasured to be 28 523 for U87 cells, and 57 993 for
HeLa cells (Fig. 2c). Both methods conrmed that MUC1
expression was considerably higher in HeLa cells than in U87
cells. These results are in agreement with the literature.47,48Cellular uptake and internalization
Flow cytometry was used to investigate the total DOX uptake by
HeLa and U87 cells for diﬀerent DOX formulations and toThis journal is © The Royal Society of Chemistry 2016evaluate receptor mediated cell targeting. The cells were treated
with samples for 2 h. Untreated control cells and treated cells
were analyzed using a BD Accuri C6 ow cytometer. As shown inRSC Adv., 2016, 6, 87910–87918 | 87915
Fig. 4 Fluorescence microscopy images of HeLa (a) and U87 cells (b).
PEGNIO/DOX/CysTAT–MUC1 was incubated with the cells for 4 h at
37 C.
Fig. 5 Cytotoxicity of the free drug and niosomal formulations on
HeLa and U87 cells. Cells were incubated with PEG/NIO, PEGNIO/
DOX, PEGNIO/DOX/CysTAT–MUC1 and free DOX (equivalent
concentration of loaded DOX) for 24 h (a) and for 48 h (b). MTT assay
was applied. Error bars represent the standard deviation from themean
(N ¼ 3). Data were analyzed using paired t-test, and *p < 0.05, **p <
0.01 was considered signiﬁcant and very signiﬁcant respectively.
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View Article OnlineFig. 3a, the cellular DOX level for PEGNIO/DOX/CysTAT–MUC1
in HeLa cells was higher than that of PEGNIO/DOX and free
DOX. Free DOX enters the cells by diﬀusion, leading to higher
drug levels than found with the PEGNIO/DOX. Aer encapsu-
lation of DOX in PEGNIO, the DOX uptake by diﬀusion is
reduced.49 In the case of U87 cells, the uptake of free DOX was
higher than PEGNIO/DOX/CysTAT–MUC1 (Fig. 3b). Fig. 3c
indicates that the synthesized PEGNIO/DOX/CysTAT–MUC1
conjugate bound to MUC1 positive HeLa cell specically.
Nonspecic binding to U87 cells was also observed, but the
uorescence signals were lower than for HeLa cells. Cellular
internalization of PEGNIO/DOX/CysTAT–MUC1 obtained by
uorescence microscopy analysis. DOX is a uorescent drug
and, it localizes to the nucleus in tumor cells.50 Both cell lines
were treated with PEGNIO/DOX/CysTAT–MUC1 for 4 h. The
synthesized conjugate bound to HeLa cells, resulting in high
uorescence of the cell nucleus, thereby demonstrating
successful internalization. In contrast, uorescence was
signicantly lower for U87 cells, indicating some nonspecic
uptake in U87 cells (Fig. 4a and b). Fluorescence microscopy
images show results similar to ow cytometry analysis.Cytotoxicity
The cytotoxicity of bare niosomes, drug loaded formulations
and free DOX was investigated by MTT assay using HeLa and
U87 cells. PEGNIO was practically nontoxic to HeLa and U87
cells with relative cell viabilities above 80% for both 24 and
48 h (Fig. 5). PEGNIO/DOX was less toxic than free DOX on
both cell lines aer 24 and 48 h. This can be explained by the
reduced diﬀusive uptake of PEGNIO/DOX in comparison to
free DOX (Fig. 3a and b).49,51 Due to the conjugation of the
targeting ligand to PEGNIO/DOX, PEGNIO/DOX/CysTAT–
MUC1 was more toxic to HeLa cells than to U87 cells aer 24
and for 48 h. Both, aer 24 and 48 hours PEGNIO/DOX/Cys-
TAT–MUC1 had less cytotoxic eﬀect of on U87 cells in
comparison with free DOX (p < 0.01 and p < 0.05 respectively).
PEGNIO/DOX/CysTAT–MUC1 increased the cytotoxicty for
HeLa cells in comparison to PEGNIO/DOX for 24 and 48
hours (p < 0.01 and p < 0.05 respectively). Moreover in87916 | RSC Adv., 2016, 6, 87910–87918comparison to free DOX, PEGNIO/DOX/CysTAT–MUC1
showed a signicantly increased toxic eﬀect on HeLa cells
aer 48 h. According to obtained results, it is clear that the
aptamer conjugated niosomal formulation acted as a tar-
geted DOX delivery platform for MUC1 expressing tumor
cells.Conclusions
The objective of this study was to develop an eﬃcient aptamer
targeted niosomal drug delivery system. For this aim, PEGNIO
was successfully synthesized by the thin lm hydration method.
The model drug DOX was encapsulated into the vesicles, and
the surface of the vesicles was decorated with cell penetrating
peptides and MUC1 aptamer as a targeting ligand. The drug-
loaded niosomes exhibit great potential as targeting drug
carriers. The targeted drug-loaded nanoparticles show stronger
cytotoxicity of the MUC1 receptor overexpressed HeLa cells. AsThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinea conclusion, the formulation PEGNIO/DOX/CysTAT–MUC1
might be a promising and eﬃcient strategy for the delivery of
DOX to MUC1 overexpressed tumor cells.Acknowledgements
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